BU

Bure Equity ABSTO Bure Equity Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

2.891

Small

Exchange

XSTO - Nasdaq STOCKHOLM AB

BURE.ST Stock Analysis

BU

Neutral

Based on Eyestock quantitative analysis, BURE.ST`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

92/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

-2.6 %

Overvalued

Market cap $B

2.891

Dividend yield

0.69 %

Shares outstanding

74.147 B

Bure Equity ABis an investment company with ownership interests in Nordic companies. The company is headquartered in Stockholm, Stockholm. The firm specializes in long-term owning, developing, as well as disposing listed and unlisted operating entities. Its holding portfolio comprises eight firms: Cavotec, an engineering group that delivers power transmission, distribution and control technologies to a range of areas; MedCap, which owns and develops companies involved in the Life Science sector; Mycronic, which designs and manufactures laser-based pattern generators that are used in the flexible electronics production; PartnerTech, providing product development, as well as production, logistics and aftermarket services; Vitrolife, a developer and producer of solutions for fertility treatment; XVIVO Perfusion AB, which focuses on organ, tissue and cell preservation in relation with transplantation; Investment AB Bure, which owns and manages leasing of locomotives; and Mercuri International, which offers sales and management training consultancy.

View Section: Eyestock Rating